Development of LAVA-1207 Discontinues in mCRPC
The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.
Related Articles
Evidence for the atavistic reversal to a unicellular‐like state as a central hallmark of cancer
Click on the article title to read more.
New data tool could bring RNA sequencing into standard clinical practice, improving diagnosis and treatment
New data tool could bring RNA sequencing into standard clinical practice, improving diagnosis and treatment
“Cell dedifferentiation” versus “evolutionary reversal” theories of cancer: The direct contest of transcriptomic features
The theory holding “cell dedifferentiation” as a hallmark of cancer and the less-well accepted “evolutionary” reversal theory are difficult to tease out experimentally. The authors…
ACS Annual Report Shows Cancer Incidence Rates Are Rising in Select Populations
The 2025 American Cancer Society Annual Report Showed incidence rates are increasing for many cancer types and disparities remain regarding cancer mortality.
TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting
The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.
Rapid, At-Home PSA Screening Test Gains Approval in UAE for Early Detection of Prostate Cancer
The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.
Risk-Stratified Approaches in Newly Diagnosed Myelofibrosis: Clinical Decision-Making for Intermediate-2 Disease
Panelists discuss how risk stratification tools and patient-specific factors guide treatment selection and timing of interventions for patients with newly diagnosed intermediate 2–risk myelofibrosis, with…
AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer
Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.
Bevacizumab Benefits in CRC Persist for Two Years After Initiation
Bevacizumab’s survival benefits in CRC patients persist for about 2 years after starting treatment.